Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kimberly Marques

Physician Assistant, Medical Norwood, MA Physician Assistant

NPI 1801411756 CMS profile 10515618

95 Chapel St Ste 2D, Norwood, MA 02062

Open in the dashboard

General payments

$6,101

348 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberly Marques of Norwood, MA is reported in the CMS Open Payments database as having received $6,101 across 348 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,774 91
2024 General $967 52
2023 General $1,007 55
2022 General $1,378 85
2021 General $974 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberly Marques
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Kimberly Marques were reported at $1,774. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Kimberly Marques Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $974 $156 $41–$563 $132
2022 $1,378 $185 $55–$649 $149
2023 $1,007 $199 $58–$717 $160
2024 $967 $206 $62–$740 $164
2025 $1,774 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,269 92 payments
  2. AstraZeneca Pharmaceuticals LP $682 38 payments
  3. Lilly USA, LLC $655 35 payments
  4. Novo Nordisk Inc $554 25 payments
  5. Pfizer Inc. $372 19 payments
  6. Novartis Pharmaceuticals Corporation $317 17 payments
  7. Amgen Inc. $272 15 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $240 13 payments
  9. GlaxoSmithKline, LLC. $226 11 payments
  10. E.R. Squibb & Sons, L.L.C. $170 9 payments
  11. Other $1,343 74 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,101 348 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $686 58 payments
  2. LINZESS $438 25 payments
  3. CREON $405 23 payments
  4. JARDIANCE $391 20 payments
  5. Ozempic $345 14 payments
  6. FARXIGA $330 18 payments
  7. NURTEC ODT $295 15 payments
  8. GEMTESA $277 13 payments
  9. MOUNJARO $211 12 payments
  10. ELIQUIS $179 9 payments
  11. Other $3,992 224 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

348 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record